04/02/2026
Genetic testing without clinical context is not precision medicine. It’s incomplete data.
A report like MTHFR, COMT, or other methylation-related markers does one thing well: it identifies genetic variants. That’s it. It does not:
- Determine clinical relevance
- Assess current physiology
- Account for medications
- Evaluate nutrient status
- Calculate safe dosing
- Cross-reference contraindications
- Account for phenotype expression
This is where risk is introduced.
Take something as common as MTHFR variants (e.g., 1298C). The presence of a SNP does not automatically dictate intervention. Yet, in many cases, protocols are suggested without:
- Reviewing SSRI/SNRI use
- Screening for bipolar spectrum
- Considering overmethylation sensitivity
- Evaluating folate/B12 status
- Assessing nitric oxide and neurotransmitter pathways
That gap matters.
Because when methylation pathways are pushed without full clinical oversight, outcomes can range from suboptimal to harmful; especially in patients with underlying psychiatric conditions, medication interactions, or nuanced biochemical profiles.
This is the reality:
Genetics tell you potential.
Clinical application determines safety.
And without both, you’re not practicing precision. You’re guessing with sophisticated data.
That’s the problem most platforms never solve. They stop at the report.
We don’t.
Our system is built to go beyond testing to interpretation, clinical integration, safety layering, and protocol design that accounts for the full picture:
- Genetics
- Biochemistry
- Medications
- Contraindications
- Individual physiology
Because the goal isn’t just to know the data.
The goal is to apply it correctly.
And when you’re working with patient health, there is no margin for error.
Interested? Let’s talk!
